CER-001
CER-001 is a recombinant high-density lipoprotein (HDL) mimetic that has orphan drug status. It is in early-stage clinical trials for the potential treatment of hypoalphalipoproteinaemia, acute coronary syndrome (ACS), acute kidney injury (AKI), atherosclerosis and lecithin cholesterol acyltransferase (LCAT) deficiency. CER-001 is also under investigation as possible agent for treating hyperinflammatory states based on lipid profile alterations due to COVID-19.
| Clinical data | |
|---|---|
| Other names | CER-001, CER 001 |
| Routes of administration | Infusion |
| Identifiers | |
| CAS Number | |
| DrugBank | |
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.